Metagenomi (MGX) Form 4: 42,000 time-vested options awarded to director

Rhea-AI Filing Summary

Metagenomi director Reid Laurence was granted a stock option covering 42,000 shares of common stock with an exercise price of $1.82. The option grant is recorded as an acquisition on 09/02/2025 and is held directly by the reporting person. The disclosed vesting schedule states that 33% of the option shares vest and become exercisable on 09/02/2026, with the remaining shares vesting in 24 equal monthly installments thereafter, subject to continued service. The option underlying shares are described as Common Stock and the reporting form is signed by an attorney-in-fact for the reporting person.

Positive

• 42,000 stock options granted to director Reid Laurence, providing equity alignment with shareholders
• Exercise price disclosed at $1.82, establishing the economic terms of the option
• Clear vesting schedule: 33% vests on 09/02/2026, remainder vests in 24 equal monthly installments

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine director equity award: 42,000 options at $1.82 with multi-year vesting; likely compensation alignment, not a market-moving event.

The grant of a 42,000-share option to a director represents a standard equity-based compensation event intended to align management and board incentives with shareholder value. The exercise price of $1.82 and the multi-stage vesting (33% after one year followed by monthly vesting over two years) indicate retention-focused design. There is no financial performance metric disclosed; the award is time-based and contingent on continued service. This filing discloses direct beneficial ownership of the option and does not show exercises, sales, or other dispositions.

Corporate Governance Expert

TL;DR: Standard governance disclosure: director received time-vested options; documentation and vesting terms are clearly stated.

The Form 4 reports a time-vested equity grant to a director with explicit vesting milestones, which meets typical Section 16 disclosure requirements. The use of an attorney-in-fact signature is noted and permissible. The filing does not indicate related-party transactions beyond a director award, nor does it disclose any performance-based conditions or acceleration clauses. From a governance perspective, the disclosure is complete for this transaction but contains no additional corporate change or related governance action.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reid Laurence

(Last) (First) (Middle)

C/O METAGENOMI, INC.

5959 HORTON STREET, 7TH FLOOR

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Metagenomi, Inc. [ MGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.82	09/02/2025		A		42,000		(1)	09/01/2035	Common Stock	42,000	$0	42,000	D

Explanation of Responses:

1. 33% of the shares subject to this option shall vest and become exercisable on September 2, 2026, with the remainder vesting in 24 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

	/s/ Matthew L. Wein, attorney-in-fact	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Reid Laurence acquire according to the Form 4 for MGX?

The Form 4 reports a grant of a stock option for 42,000 shares of Metagenomi common stock to Reid Laurence.

What is the exercise price of the option reported on the MGX Form 4?

The exercise (conversion) price is reported as $1.82 per share.

When do the option shares begin to vest?

The filing states 33% of the option shares vest and become exercisable on 09/02/2026, with the remainder vesting monthly over the following 24 months.

Is the option ownership direct or indirect?

The Form 4 indicates the option is held directly (D) by the reporting person.

Does the Form 4 show any exercises, sales, or dispositions by the reporting person?

No; the Form 4 only reports an acquisition (grant) of a stock option and does not report any exercises or dispositions.